Skip to main
GILD

Gilead Sciences (GILD) Stock Forecast & Price Target

Gilead Sciences (GILD) Analyst Ratings

Based on 16 analyst ratings
Buy
Strong Buy 38%
Buy 50%
Hold 13%
Sell 0%
Strong Sell 0%

Bulls say

Gilead Sciences is experiencing a positive outlook driven by anticipated revenue growth from its oncology portfolio, particularly following the expected approval of Trodelvy for 1L mTNBC, with revenue estimates raised to over $1.0 billion at peak based on strong quarterly sales of Livdelzi and the potential expansion of its label. The company has also achieved a milestone in payer coverage, hitting a 90% goal ahead of schedule, which strengthens its market position amid competitive challenges. Additionally, solid revenue growth in the HIV franchise, coupled with disciplined operating expenses and improving operating margins, further supports Gilead's favorable financial trajectory.

Bears say

Gilead Sciences's outlook appears negative due to the significant downward revisions in revenue guidance for its antiviral drug Veklury, which is projected to generate only $1.0 billion in FY25, down from the previous estimate of $1.4 billion, with a further decline to $600 million anticipated in 2026. The company's cell therapy franchise has also encountered competitive challenges, leading to a 6% year-over-year decline in revenue to $458 million and a forecasted revenue drop of 10% in 2026. Additionally, ongoing policy-related headwinds and the decreasing relevance of Veklury's sales to total revenues cast further uncertainty on Gilead's financial trajectory.

Gilead Sciences (GILD) has been analyzed by 16 analysts, with a consensus rating of Buy. 38% of analysts recommend a Strong Buy, 50% recommend Buy, 13% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Gilead Sciences and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Gilead Sciences (GILD) Forecast

Analysts have given Gilead Sciences (GILD) a Buy based on their latest research and market trends.

According to 16 analysts, Gilead Sciences (GILD) has a Buy consensus rating as of Mar 25, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $148.75, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $148.75, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Gilead Sciences (GILD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.